EMERGENT BIOSOLUTIONS INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 2.02 Results of Operations and Financial Condition.

On January 9, 2022, Emergent BioSolutions Inc. (the "Company") announced preliminary unaudited financial results for 2021 and guidance for 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. During the week of January 10, 2022, representatives of the Company will participate in the 40th Annual J.P. Morgan Healthcare Conference and these Company representatives will present the slides furnished as Exhibit 99.2 to this Current Report on Form 8-K, which are incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.                                                Description
                              Press release issued by the Company on     January     09    ,
99.1                        202    2    .
99.2                          Corporate slide deck, dated January 10, 2022.
101                         Emergent BioSolutions Inc. Current Report on Form 8-K, dated January 9,
                            2022 formatted in XBRL (Extensible Business Reporting Language): Cover
                            Page. The instance document does not appear in the Interactive Data File
                            because its XBRL tags are embedded within the Inline XBRL document.
104                         Cover Page Interactive Data File (formatted as Inline XBRL and contained
                            in Exhibit 101).

© Edgar Online, source Glimpses